Indegene Trades 61% Below Graham Number

Indegene's Graham Discount: Opportunity or Optical Illusion? [Indegene](/stock/INDGN) (NSE: INDGN) is trading at ₹555.80, a level that places it 61.2% below its computed Graham Number of ₹1,278.09 — the widest margin of safety in FairStock.ai's current screen. That's a striking gap by any arithmetic measure. The Graham Number, derived from a stock's earnings per share and book value per share, was designed by Benjamin Graham as a ceiling price for defensive investors. When a stock trades well under that ceiling, the traditional read is that the market is offering a discount. But Indegene isn't a utility or a bank. It's a healthcare technology company with a P/E of 33.44, and that changes the conversation considerably. The disconnect between a high earnings multiple and a deep Graham discount isn't a contradiction — it's a tension that demands explanation. Graham's formula rewards high book value and strong earnings simultaneously. If Indegene's book value is substantial relative to its current price while earnings remain solid, the formula produces a high Graham Number even when the P/E looks stretched by value-investing standards. The FairStock Score of 70 for INDGN sits at the threshold of what the platform considers a reasonably valued stock, suggesting the data isn't uniformly bearish or uniformly bullish. It's genuinely mixed. Indegene went public on Indian exchanges in May 2024 at an issue price of ₹452, listing at a premium. The stock ran past ₹700 in mid-2024 before pulling back to current levels near ₹555. That trajectory matters. The current price reflects a market that priced in growth expectations on listing, watched execution, and then repriced — not a stock that has been chronically ignored. What the P/E of 33 Actually Tells You A P/E of 33.44 in the Indian mid-cap technology space is neither alarming nor cheap. For context, comparable healthcare IT names have historically traded in the 25–45x range when revenue growth is running above 20% annuall...